News & Events

25 September 2022

Masterclass by Thomas Berg now online

In our newest Masterclass on YouTube, Prof. Dr. Thomas Berg, Head of Hepatology at ULEI and Secretary General of EASL, provides an in-depth overview of the current clinical challenges and newest treatment advances for patients suffering from cirrhosis and ACLF. The Masterclass was recorded during the 2nd A-TANGO General Assembly (GA) Meeting in Barcelona, Spain, on 11 May 2022. More E-Learning.

22 September 2022

Watch our video series from #ILC2022

Following the patients' interest in A-TANGO, we experimented with a new communication format during the International Liver Congress (#ILC2022) in London in June 2022 and recorded several video interviews by representatives of the European Liver Patients' Association (ELPA) with Dr. med. Cornelius Engelmann (Charité), co-coordinator of A-TANGO and supervisor of the clinical G-TAK study. Watch the videos!

8 August 2022

Masterclass by Daniel Green on YouTube

Daniel Green – project partner, entrepreneur, and CEO of Yaqrit (YAQ) – held an interactive and fun Masterclass on “Medical Device Design, Biotechnology and Entrepreneurship” during the 2nd A-TANGO General Assembly (GA) Meeting in Barcelona, Spain, on 11 May 2022. The Masterclass is now available on YouTube. If you want to learn more, check out our E-Learning page.


More than 10 million people worldwide suffer from decompensated cirrhosis, often as a result of severe alcoholic hepatitis (sAH) or other chronic liver diseases. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterized by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

Read more


  • Obtain ethical and regulatory approval of the planned clinical studies
  • Ensure safe and regulated supply of the required drugs and placebos
  • European multicenter clinical study to establish the safety, pharmacokinetics, and efficacy of our novel therapeutic strategy
  • Explore the pathophysiological mechanisms and evaluate biomarkers
  • Evaluate our results with respect to clinical outcome, treatment impact, and quality of life
  • Exploit our results by identifying economic benefits for the healthcare system, reimbursement strategies, and potential commercial interest
  • Disseminate the therapeutic potential of our novel treatment strategy to stakeholders and increase awareness of end-stage liver disease

Read more


Prof. Dr. Rajiv Jalan (EF CLIF)
Travessera de Gràcia 11, 7th floor
08021 Barcelona


Dr. med. Cornelius Engelmann (Charité)
Augustenburger Platz 1
13353 Berlin


concentris research management gmbh
Ludwigstr. 4
82256 Fürstenfeldbruck